Screener
CG Oncology CGON Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 5,730 | 3,971 |
| Intangible assets, net | 545 | 575 |
| Goodwill | 10,297 | 10,297 |
| Other assets | 4,729 | 1,678 |
| Total assets | $1,085,655 | $791,592 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,727 | $5,714 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's deferred tax assets and other non-current assets?
- CG Oncology (CGON) reported deferred tax assets and other non-current assets of $4.73M in Q2 2026.
- How has CG Oncology's deferred tax assets and other non-current assets changed year-over-year?
- CG Oncology's deferred tax assets and other non-current assets increased by 805.9% year-over-year, from $522K to $4.73M.
- What is the long-term trend for CG Oncology's deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), CG Oncology's deferred tax assets and other non-current assets has grown at a 839.8% compound annual growth rate (CAGR), from $19K to $1.68M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about CG Oncology's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude